Plain-English translation of NCT07704164 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether colchicine, a medication already known to help with heart inflammation in other patients, can reduce inflammation in the coronary arteries (the blood vessels that feed your heart) in people living with HIV. People with HIV have a higher risk of heart disease even when their virus is well-controlled, partly because of ongoing inflammation in their blood vessels. This study will see if this medication can help protect your heart.
Despite modern HIV treatments that control the virus well, people with HIV still have higher rates of heart disease than the general population. Scientists believe persistent inflammation in blood vessels plays a major role, and current treatment options for this specific problem are limited. This trial is testing whether this medication could offer a new way to reduce that inflammation and lower heart disease risk.
You likely qualify if…
You likely don't qualify if…
You would take either the study medication or a placebo pill (a dummy pill with no active ingredient) once daily by mouth for 96 weeks—about 2 years. During this time, you'll have follow-up visits where researchers will perform heart imaging scans (a special CT scan of your heart arteries) and blood tests to measure inflammation and heart health markers. Neither you nor the researchers will know which group you're in until the study ends, which helps keep the results fair and unbiased.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
Spain